B
BrightGene
Complex APIs, formulations and innovative drugs from Suzhou
About BrightGene
BrightGene Bio-Medical (博瑞医药, SSE STAR 688166) is a Suzhou-based pharmaceutical company specializing in complex generic APIs, finished dosage forms, and innovative drug R&D. Founded in 2001, BrightGene builds on fermentation semi-synthesis and multi-chiral chemistry platforms to supply high-barrier APIs and formulations across oncology, anti-infectives, immunology, cardiovascular, and respiratory indications, with products registered in multiple major markets. Public filings put headcount around 1,150 employees, far above a micro-startup band. The company is expanding from complex generics into innovative assets and synthetic-biology adjacent ingredients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2001
- Headquarters
- Suzhou Shi, China
- Listing
- IPO 2019
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 40.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Investment activity
- 2 companies, latest Jan 2024
- Capital deployed
- $23M
- Preferred round
- EARLY VC
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2025 | $69M | — | Undisclosed | ↗ |
| IPOOther financing | Nov 2019 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $168M | 0% | $36M | 21.3% |
| 2025 | $168M | -4.6% | $36M | 21.3% |
| 2024 | $176M | +8.7% | $49M | 28% |
| 2023 | $162M | +15.9% | $46M | 28.3% |
| 2022 | $140M | -3.3% | $46M | 32.7% |
| 2021 | $145M | +34% | $45M | 31.1% |
| 2020 | $108M | — | $33M | 30.3% |
Growth signals
Latest recorded traffic for BrightGene is 1.6K monthly website visits, down 95.4% over the last three months. BrightGene's team grew 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shenzhen Aoli BiotechnologyShenzhen, ChinaA professional GPS tracker factory which has 8 years experience in GPS industry
$11Mvaluation
CitryllOss, NetherlandsDevelops therapeutics targeting the neutrophil extracellular trap (NET) pathway to treat inflammatory diseases, with its lead antibody, CIT-013, in clinical trials for rheumatoid arthritis and hidradenitis suppurativa
$374Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Highlight Capital
Other known investors3 additional known investors
HSG
SDIC Fund Management
Sequoia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BrightGene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BrightGene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.